# Accumulate



### Volume de-growth due to economic slowdown and lockdown.

- Results were in line with our estimates on revenue front and below estimates on profitability front.
- CSTRL's Q2CY20 volumes were in line with our estimates at 29 TKL. Realization was at Rs 169.2/L. Revenue decreased 52.8% YoY and 28.7% sequentially due to lockdown. However, there was slow demand pick up from May and momentum was stable from June.
- Gross spreads decreased by 16.9% on a sequential basis. We expect spreads to expand going forward, as CIL will keep taking pricing actions as and when required and will take necessary steps to keep cost in control. Cost per litre improved 4.8% on a sequential basis and declined by 4.8% YoY due to strategic sourcing of raw material.
- CIL has been continuously working on protecting margins with sustainable growth. Given the under performance of the stock price for a prolonged period, CSTRL business performance in the next couple of quarters will be crucial for the long term stock outlook. Recommend Accumulate, with a target price of Rs 130, to trade at 16x CY21 EPS.

#### Volume growth – key monitorable

CSTRL reported a volume de-growth of 23% QoQ and 48% YoY. Personal mobility segment which is 45% of the mix for Castrol had seen a slowdown due to sales lost as nationwide lockdown was announced and also factories were shut and there was freight movement reduction which affected the overall volumes. However, momentum in June had stabilized. Recovery was seen faster in 2W as compared to CV and passenger vehicles. Agriculture segment has seen a good pick up towards the end of April and May month but was much lower YoY. Usually, Q2CY20 is a high volume good quarter for CSTRL due to the demand from agriculture segment, however some sales were lost for the quarter as the economy has not fully opened up and parts of India are still under lockdown. CSTRL expects pent up demand to come in from the personal mobility segment but the demand will be slow for next few months. However, the demand for lubes can also be deferred by customers.

They have new product launches for the personal mobility segment and marketing programs in place for next year, which will be introduced looking at the economic situation. Management has not guided any volume growth due to the uncertain situations.

## Q2CY20 Result (Rs Mn)

Particulars	Q2CY20	Q2CY19	YoY (%)	Q1CY20	QoQ (%)
Revenue	4,906	10,396	(52.8)	6,880	(28.7)
Total Expense	3,953	7,553	(47.7)	5,150	(23.2)
EBITDA	953	2,843	(66.5)	1,730	(44.9)
Depreciation	206	166	24.1	222	(7.2)
EBIT	747	2,677	(72.1)	1,508	(50.5)
Other Income	152	159	(4.4)	198	(23.2)
Interest	14	3	366.7	11	27.3
EBT	885	2,833	(68.8)	1,695	(47.8)
Тах	231	1,006	(77.0)	443	(47.9)
RPAT	654	1,827	(64.2)	1,252	(47.8)
APAT	654	1,827	(64.2)	1,252	(47.8)
		-	(bps)	-	(bps)
Gross Margin (%)	51.3	53.9	(260)	57.0	(574)
EBITDA Margin (%)	19.4	27.3	(792)	25.1	(572)
NPM (%)	13.3	17.6	(424)	18.2	(487)
Tax Rate (%)	26.1	35.5	(941)	26.1	(3)
EBIT Margin (%)	15.2	25.8	(1052)	21.9	(669)

СМР	Rs 113
Target / Upside	Rs 130 / 15%
BSE Sensex	38,469
NSE Nifty	11,301
Scrip Details	
Equity / FV	Rs 4,946mn / Rs 5
Market Cap	Rs 112bn
	USD 1bn
52-week High/Low	Rs 162/Rs 90
Avg. Volume (no)	1,305,750
NSE Symbol	CASTROLIND
Bloomberg Code	CSTRL IN
Shareholding Patte	ern June'20(%)
Promoters	51.0
MF/Banks/FIs	18.5
FIIs	9.0
Public / Others	21.5

#### Valuation (x)

	CY19A	CY20E	CY21E
P/E	13.5	18.4	13.9
EV/EBITDA	8.9	12.1	9.1
ROE (%)	65.3	49.1	74.8
RoACE (%)	68.5	51.4	77.8

## Estimates (Rs mn)

	CY19A	CY20E	CY21E
Revenue	38,768	32,627	36,607
EBITDA	11,531	8,483	11,348
PAT	8,274	6,074	8,029
EPS (Rs.)	8.4	6.1	8.1

AVP Research: Nidhi Doshi Tel: +91 22 40969795 E-mail: nidhid@dolatcapital.com





## Expanding reach with brand thrust - key to profitability

CSTRL has been expanding distribution aggressively to increase its touch points. They are making inroads in rural markets by adding new customers directly or indirectly. The company is also investing in brands and retail distribution and will continue to do so. They have opened up 500 retail outlets virtually in Q2CY20. We expect CSTRL to maintain its investments in the distribution chain and advertising to get "profitable volume growth"

### New product launches and moving into adjacencies to drive growth

CSTRL is adding new products, with improved formulations and performance across categories. They are ready with BSVI range of products across categories to be launched soon. They have entered into agreements for EV fluids with OEMs in India including MG Motors and Tata Motors, as well as to supply lubricants to various OEMs for their BS-VI compliant vehicles.

They have signed a strategic alliance with the Jio-bp fuel retail network which will enable CSTRL lubricants enhanced reach and visibility at 1,400 Jio-bp retail sites across the country, which are planned to expand to 5,500 sites in the next five years. CSTRL lubricants will be the sole supplier of lubricants at these sites. This is a new growth engine for CSTRL as they did not have their presence is this area.

Particulars	Q2CY20	Q1CY20	QoQ (%)	Q2CY19	YoY (%)	H1CY20	H1CY19	YoY (%)
Volumes (in '000 KL)	29.0	37.6	(22.9)	55.4	(47.7)	66.6	105.8	(37.1)
Realization (Rs / L)	169.2	183.0	(7.5)	187.7	(9.8)	177.0	190.5	(7.1)
Cost (Rs / L)	82.4	78.6	4.8	86.5	(4.8)	80.2	88.5	(9.3)
Spread (Rs / L)	86.8	104.4	(16.9)	101.2	(14.2)	96.7	102.1	(5.2)
EBIDTA (Rs / L)	32.9	46.0	(28.6)	51.3	(36.0)	40.3	53.6	(24.9)
PAT (Rs / L)	22.6	33.3	(32.3)	33.0	(31.6)	28.6	34.8	(17.7)

#### Exhibit 1: KPI's

Source: Company, DART

### Exhibit 2: Actual V/s DART Estimates

Rs mn	Actual	Estimates	Variance (%)	Comments
Revenue	4,906	5,068	(3.2)	
EBITDA	953	1,366	(30.2)	Lower realisation and higher raw material cost
EBITDA margin %	19.4	27.0	(752.8)	
APAT	654	973	(32.8)	

Source: Company, DART

# Exhibit 3: Change in estimate

Particulars (Rs mn)	CY20E				CY21E	
	New	Old	Chg (%)	New	Old	Chg (%)
Revenue	32,627	34,981	(6.7)	36,607	38,713	(5.4)
EBITDA	8,483	10,634	(20.2)	11,348	11,924	(4.8)
EBITDA mgn (%)	26.0	30.4	(440.0)	31.0	30.8	20.0
Adj PAT	6,074	7,773	(21.9)	8,029	8,610	(6.7)
EPS (Rs)	6.1	7.9	(21.9)	8.1	8.7	(6.7)

Source: Company, DART





# **Key Highlights**


- The top line in Q2CY20 decreased by 52.8% on a YoY basis to Rs. 4,906 mn, which was a decline of 28.7% on a QoQ basis.
- Raw material as a % of sales was at 49% in Q2CY20 as compared to 43% in Q1CY20 and 46% in Q2CY19.
- EBIDTA has decreased by 66.5% on a YoY to Rs. 953 mn.
- Operating margins were at 19.4% which decline on a QoQ basis by 572 bps and by 792 bps on a YoY basis.
- Net profit has decreased by 64.2% on a YoY basis and by 47.8% on a sequential basis to Rs. 654 mn.

# **Conference Call Key Highlights**

- The continued slowdown in economy, uncertainty around BSVI vehicles, liquidity crunch due to the ongoing Pandemic resulted in a decline in lubricants consumption.
- There was a cash burn of Rs. 90 cr in Q2CY20
- In H1CY20 Automotive contributed 90% and rest was non-automotive.
- Advertisement spend was very low for the quarter as there was no demand for the products.
- The capex Spend at Silvassa has slowed down due to the lockdown. Going ahead, capex spend will be more on personal mobility segment.
- Personal mobility was better towards June. Some demand was there from CV due to agri season.
- Revenue Mix: 45% is personal mobility and balance is industrial and commercial. Contribution from OEM's is 10% of volumes.
- Stable demand is seen from July. Demand has started picking up from May'20. Demand pick up is seen more in 2W segment. May and June are harvest seasons. Recovery is faster in 2W as compared to CV and passenger cars.










Source: Company, DART






Source: Company, DART






Source: Company, DART


Exhibit 5: EBIDTA spread(Rs/L)and EBIDTA margin(%)




Source: Company, DART



Source: Company, DART





Source: Company, DART





Profit and Loss Account
-------------------------

(Rs Mn)	CY18A	CY19A	CY20E	CY21E
Revenue	39,046	38,768	32,627	36,607
Total Expense	28,338	27,238	24,144	25,259
COGS	19,066	17,477	15,008	16,107
Employees Cost	2,034	2,131	1,958	1,830
Other expenses	7,238	7,630	7,178	7,321
EBIDTA	10,708	11,531	8,483	11,348
Depreciation	556	697	931	1,201
EBIT	10,152	10,834	7,552	10,147
Interest	11	12	35	17
Other Income	843	648	600	600
Exc. / E.O. items	0	0	0	0
EBT	10,984	11,469	8,117	10,730
Tax	3,901	3,195	2,043	2,701
RPAT	7,084	8,274	6,074	8,029
Minority Interest	0	0	0	0
Profit/Loss share of associates	0	0	0	0
АРАТ	7,084	8,274	6,074	8,029

Balance Sheet				
(Rs Mn)	CY18A	CY19A	CY20E	CY21E
Sources of Funds				
Equity Capital	4,946	4,946	4,946	4,946
Minority Interest	0	0	0	0
Reserves & Surplus	6,711	8,724	6,119	5,469
Net Worth	11,657	13,670	11,065	10,415
Total Debt	0	0	0	0
Net Deferred Tax Liability	(533)	(585)	(400)	(400)
Total Capital Employed	11,124	13,085	10,665	10,015

Net Block	1,860	1,997	2,316	2,365
CWIP	350	273	250	250
Investments	0	0	0	0
Current Assets, Loans & Advances	18,325	19,432	18,107	18,001
Inventories	4,568	3,047	2,682	2,808
Receivables	3,918	4,820	4,112	4,614
Cash and Bank Balances	7,439	9,460	9,386	8,813
Loans and Advances	1,259	1,447	1,302	1,172
Other Current Assets	1,142	658	625	593
Less: Current Liabilities & Provisions	9,411	8,618	10,008	10,600
Payables	5,840	4,718	5,757	6,178
Other Current Liabilities	3,571	3,900	4,251	4,422
sub total				
Net Current Assets	8,913	10,814	8,099	7,400
Total Assets	11,124	13,085	10,665	10,015
E – Estimates				







Particulars	CY18A	CY19A	CY20E	CY218
(A) Margins (%)				
Gross Profit Margin	51.2	54.9	54.0	56.0
EBIDTA Margin	27.4	29.7	26.0	31.0
EBIT Margin	26.0	27.9	23.1	27.7
Tax rate	35.5	27.9	25.2	25.2
Net Profit Margin	18.1	21.3	18.6	21.9
(B) As Percentage of Net Sales (%)				
COGS	48.8	45.1	46.0	44.(
Employee	5.2	5.5	6.0	5.0
Other	18.5	19.7	22.0	20.0
(C) Measure of Financial Status				
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	931.4	902.8	215.8	596.9
Inventory days	43	29	30	28
Debtors days	37	45	46	46
Average Cost of Debt				
Payable days	55	44	64	62
Working Capital days	83	102	91	74
FA T/O	21.0	19.4	14.1	15.5
(D) Measures of Investment				
AEPS (Rs)	7.2	8.4	6.1	8.1
CEPS (Rs)	7.7	9.1	7.1	9.3
DPS (Rs)	5.0	5.5	7.5	7.5
Dividend Payout (%)	69.8	65.7	122.1	92.4
BVPS (Rs)	11.8	13.8	11.2	10.5
RoANW (%)	64.8	65.3	49.1	74.8
RoACE (%)	68.3	68.5	51.4	77.8
RoAIC (%)	369.6	296.4	308.1	818.2
(E) Valuation Ratios				
CMP (Rs)	113	113	113	113
P/E	15.8	13.5	18.4	13.9
Mcap (Rs Mn)	111,721	111,721	111,721	111,721
MCap/ Sales	2.9	2.9	3.4	3.1
EV	104,283	102,261	102,335	102,908
EV/Sales	2.7	2.6	3.1	2.8
EV/EBITDA	9.7	8.9	12.1	9.1
P/BV	9.6	8.2	10.1	10.7
Dividend Yield (%)	4.4	4.9	6.6	6.6
(F) Growth Rate (%)				
Revenue	8.9	(0.7)	(15.8)	12.2
EBITDA	3.6	7.7	(26.4)	33.8
EBIT	2.8	6.7	(30.3)	34.4
PBT	2.6	4.4	(29.2)	32.2
APAT	2.4	16.8	(26.6)	32.2
EPS	2.4	16.8	(26.6)	32.2

(4,482)	9,781 7,647 (8,714)	(1,251) (8,696)
(4,482) (6,277)	7,647 (8,714)	(1,251) (8,696)
(6,277)	(8,714)	(8,696)
7,802	8,555	8,124
2,636	672	9,386
672	9,386	8,813
	_,	_,





# DART RATING MATRIX

Total Return Expectation (12 Months	<b>Total Return</b>	Expectation	(12 Months)	)
-------------------------------------	---------------------	-------------	-------------	---

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

# **Rating and Target Price History**



Co- Head Asia Derivatives

**VP** - Derivatives Strategist

Dinesh Mehta

Bhavin Mehta

Jul-19 Accumulate 143 125   Oct-19 Accumulate 172 154   Feb-20 Accumulate 163 147   Mar-20 Buy 128 95   Jun-20 Accumulate 131 117	Month	Rating	TP (Rs.)	Price (Rs.)
Feb-20 Accumulate 163 147   Mar-20 Buy 128 95   Jun-20 Accumulate 131 117	Jul-19	Accumulate	143	125
Mar-20 Buy 128 95   Jun-20 Accumulate 131 117	Oct-19	Accumulate	172	154
Jun-20 Accumulate 131 117	Feb-20	Accumulate	163	147
	Mar-20	Buy	128	95
	Jun-20	Accumulate	131	117
Jun-20 Accumulate 139 127	Jun-20	Accumulate	139	127

\*Price as on recommendation date

dinesh.mehta@dolatcapital.com +9122 4096 9765

+9122 4096 9705

bhavinm@dolatcapital.com

# DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747
Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745
	CONTACT DETAI	LS	
Equity Sales	Designation	E-mail	Direct Lines
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735
Yomika Agarwal	VP - Equity Sales	yomika@dolatcapital.com	+9122 4096 9772
Jubbin Shah	VP - Derivatives Sales	yomika@dolatcapital.com	+9122 4096 979
Ashwani Kandoi	AVP - Equity Sales	ashwanik@dolatcapital.com	+9122 4096 9725
Lekha Nahar	AVP - Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740
Equity Trading	Designation	E-mail	
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715

**Dolat** Capital Market Private Limited. Sunshine Tower, 28th Floor, Senapati Bapat Marg, Dadar (West), Mumbai 400013



#### Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

#### I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

#### II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: This research report is a product of Dolat Capital Market Private Limited., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Dolat Capital Market Private Limited. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited. has entered into an agreement with a U.S. registered brokerdealer Ltd Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer/Entity as informed by Dolat Capital Market Private Limited. from time to time.

#### Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797 Member: BSE Limited and National Stock Exchange of India Limited. SEBI Registration No: BSE - INB010710052 & INF010710052, NSE - INB230710031& INF230710031, Research: INH000000685 Registered office: Office No. 141, Centre Point, Somnath, Daman – 396 210, Daman & Diu Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com